Scientists believe a targeted drug delivery system could make ovarian cancer more treatable for the most deadly gynecological cancer in the United States. In animal research, the cancer is attacked at the genetic level by using small, inhibiting RNA molecules that directly target and decrease the excess CD44 protein in cancer cells while simultaneously treating patients with the anti-cancer drug paclitaxel. This allows cells within the cancerous tumors to be successfully treated even at an advanced stage.